What will happen to the CRO industry whilst the economy improves

We may speculate what will happen to the clinical research organisation (CRO) industry while the nation gradually improves from the recent recession, but according to a recent reportperformed by Frost & Sullivan, the CRO industry will continue to grow. During this current environment, biotech and pharma organisations are less probable to rely on or invest in internal methods to perform their drug trials. However, someone has to do them…

The report has also warned that the “US CRO Markets-Key Therapeutic Areas” anticipate that struggling pharma and biotech companies will fail to meet the costs for trials currently underway. But this is not likely to be a lasting occurrence, suggests the report.

Barath Shankar Subramanian, senior industry analyst for Frost and Sullivan, pointed out that the CRO annual revenue growth is down from the fourteen to fifteen percent region last year to ten percent this year.

Expansion Forecasts – for pharmacology companies or CRO’s

However, he says that the good news is that it is anticipated that the annual revenues for the industry will increase twofold between now and the year 2015, increasing from $10.91 billion at present to $22.87 billion. He says this is likely to result of sponsor organisations assuming strategic alliances with services organisations or smaller CROs. “After 10 years of talking about such relationships, CROs and pharma companies are beginning to forge them,” Subramanian says.

Subramanian uses the huge Eli Lilly/Covance deal made in August last year to exemplify this claim, where Covance has contracted out $1.6 billion worth of drug development projects to Lilly for the next 10 years.

Subramanian says: “That’s the flavor of the season, we’re seeing some new models being explored when previously it was purely transactional, with CROs taking a wait and watch attitude toward strategic partnerships.”

In addition, partnerships with CROs or clinical pharmacology organisations enable small sponsors more time within the research cycle to investigate promising molecules. Beginner biotech and pharma firms used to out-licence their Phase I or Phase II; which resulted in a large amount of ambiguity for the future of the research study. In this day and age, conversely, more and more start-up firms are able to keep products in the pipeline for a longer period of time which in turn brings them closer to the market and this is due to the cost-effectiveness made possible by CROs. This is an optimistic outcome for the sponsor and the CRO.

Tip from the Author: clinical studies conducted in the UK by a professional institute of clinical research is the best choice for aquiring the most accurate data.

* Make sure that you consult your doctor before taking any medical advice of any kind.